• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The 3rd Beijing Forum of Evidence-Based Medicine and 2023 Cochrane China Network Symposium successfully held
Cochrane China recently hosted a virtual event for the evidence-based medicine community that brought together many of its partners, local expertise, and international speakers. Here the team provides an overview of who was involved and what was covered at the event.  The3rd Beijing forum of evidence-based medicine and Cochrane China Network  Symposium was successfully held virtually on January 15th, 2023. The host of this conference wereCochrane China Network and Beijing GRADE Center. The organizers are Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, affiliate of the Cochrane China Ne...
Source: Cochrane News and Events - February 17, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 Exposed the Faults in America ’s Elder Care System. This Is Our Best Shot to Fix Them
For the American public, one of the first signs of the COVID-19 pandemic to come was a tragedy at a nursing home near Seattle. On Feb. 29, 2020, officials from the U.S. Centers for Disease Control and Prevention (CDC) and Washington State announced the U.S. had its first outbreak of the novel coronavirus. Three people in the area had tested positive the day before; two of them were associated with Life Care Center of Kirkland, and officials expected more to follow soon. When asked what steps the nursing home could take to control the spread, Dr. Jeff Duchin, health officer for Seattle and King County, said he was working w...
Source: TIME: Health - June 15, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging COVID-19 feature franchise Magazine TIME for Health Source Type: news

PNR Weekly Digest: April 6, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: Understanding End-of-Life Matters Whether your focus of concern is on a family member or yourself, this April the NNLM Reading Club suggests three books that may help with your understanding of end-of-life matters and those conversations you probably have been putting off…read the post to see the book selections Professional Development: NNLM CE Opportunities: NNLM offers training on a variety of topics related to health information. A complete listing of NNLM educational opportunities is available. Please note you need to create an NNLM accou...
Source: Dragonfly - April 6, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

ASA: Herpes Zoster Vaccine May Reduce Risk for Stroke
WEDNESDAY, Feb. 12, 2020 -- Vaccination with zoster vaccine live (ZVL) is associated with a reduced risk for stroke among older adults, according to a study to be presented at the American Stroke Association International Stroke Conference, held...
Source: Drugs.com - Pharma News - February 12, 2020 Category: Pharmaceuticals Source Type: news

SwitchPoint 2019: Day 1
By Margarite Nathe, Principal Editor/Writer, IntraHealth InternationalApril 25, 2019It takes tenacity to work in global health and development. These folks have it.I ’m going to go out on a limb and guess that if you work in global health or international development, you might know what frustration feels like.Maybe the project funding cycle gets you down. Maybe you ’ve struggled with a public policy that hurts more people than it helps. It could be that you’ve grappled with shoddy data sets, or corrupt officials, or the fickle winds of politics that so often blow our efforts off course.You need tenacity to do th...
Source: IntraHealth International - April 26, 2019 Category: International Medicine & Public Health Authors: mnathe Tags: SwitchPoint Source Type: news

Promoting evidence-based health care in Africa
Charles Shey Wiysonge, Director ofCochane  South Africa, gave an interview to the World Health Organization Bulletin. Here is a re-post , with premission, from their  recent publication.Charles Shey Wiysonge is devoted to encouraging better use of scientific evidence for health policies and programmes in African countries. He is the director of the South African Cochrane Centre, a unit of the South African Medical Research Council, and a professor of epidemiology and biostatistics at the department of Global Health in the Faculty of Medicine and Health Sciences at Stellenbosch University in South Africa. He was Chief Res...
Source: Cochrane News and Events - August 17, 2017 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Carlos Juan Finlay: Cuban physician celebrated in Google doodle
Cuban physician and scientist, who would have been 180 today, developed theory that yellow fever was spread by mosquitoesGoogle's latest doodle celebrates the birthday of Carlos Finlay, the Cuban physician and scientist who theorised that yellow fever was spread by mosquitoes.Of French and Scottish descent, Finlay was born in 1833 in Puerto Príncipe, now the Cuban city of Camagüey, and studied at Jefferson medical college in Philadelphia, Pennsylvania. He finished his studies in Havana and Paris before settling in Cuba to open a medical practice.Finlay was appointed by the Cuban government in 1879 to work with a North Am...
Source: Guardian Unlimited Science - December 3, 2013 Category: Science Tags: theguardian.com Search engines Google doodle Biology World news Medical research Technology Internet Science Source Type: news

157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June: Accurate Results in the Clinical Laboratory Adult Emergency Medicine Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.) Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.) Advancing Your Career: Concepts of Professional Nursing (5th ed.) Arrhythmia Essentials Atlas of Advanced Operative Surgery Atlas of Clinical Neurology (3rd ed.) Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches Atlas of Human Infectious Diseases Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news